NASDAQ:ABUS
Arbutus Biopharma Corporation Stock Signals
Latest Data & Signals Issued
| Signal Type | Signal Value | Data | |
|---|---|---|---|
| Score | 0.917 | 12 days ( -1.35 % ) | |
| Last Price | $3.00 | -1.96 % | |
| High/ Low | $3.00 - $3.12 | 4.50% | |
| Chg 7 Days | -0.99 % | $3.03 $3.00 | |
| Chg 30 Days | 13.21 % | $2.65 $3.00 | |
| Chg 12 mos | 4.53 % | $2.87 $3.00 | |
| Trend - 3 mos | 17.08 % | Width: 15.21 % | |
| Trend - 12 mos | 8.49 % | Width: 52.99 % | |
| Pred. range - 3 mos | $3.12 - $3.59 | 3.91 % - 19.71 % | |
| Pred. range - 12 mos | $2.17 - $3.32 | -27.65 % - 10.69 % | |
| Short mv avg 3 mos | Sell | 2023-03-27 - 2 days | |
| Long mv avg 3 mos | Sell | 2023-03-09 - 14 days | |
| Short/Long mv avg 3 mos | Buy | 2023-03-06 - 17 days | |
| Short mv avg 12 mos | Sell | 2023-03-21 - 6 days | |
| Long mv avg 12 mos | Buy | 2023-01-05 - 57 days | |
| Short/Long mv avg 12 mos | Buy | 2022-11-07 - 97 days | |
| Pivot Short | Sell | 2023-03-27 - 2 days | |
| Bollinger | Buy | 2023-03-15 - 10 days | |
| MACD | Buy | No Dates Stored For This Signal |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel ... ABUS Profile
Top Fintech Company
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
